Different fibrotic interstitial lung diseases share demographic and functional similarities despite having different causes.

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported significant improvements in functional independence from rehabilitation entry to discharge.

Despite its effectiveness, pulmonary rehabilitation (PR) is underused and under-prescribed. The expert panel charged with developing guidance for practitioners is hopeful that the latest Clinical ...

The global burden of ILD and pulmonary sarcoidosis increased by 169% from 1990 to 2021, with high-SDI countries most affected. ILDs, including idiopathic pulmonary fibrosis, have a poor prognosis, ...

Nerandomilast improved FVC in the FIBRONEER-ILD trial, meeting its primary end point in patients with progressive pulmonary fibrosis. Safety and tolerability results were consistent with previous ...